Universal influenza vaccination: The time to act is now

Biosecurity and Bioterrorism

Volumn 4, Issue 1, 2006, Pages 20-40

  Mair, Michael ^a   Grow, Robert W ^b   Mair, Julie Samia ^c   Radonovich Jr , Lewis J ^d,e  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b MAYO CLINIC   (United States)

^c GEORGETOWN UNIVERSITY   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE;

BIOLOGICAL WARFARE; COST OF ILLNESS; DISASTER PLANNING; ECONOMICS; HEALTH CARE COST; HUMAN; INFLUENZA; MASS IMMUNIZATION; METHODOLOGY; ORGANIZATION AND MANAGEMENT; PRACTICE GUIDELINE; PUBLIC HEALTH SERVICE; PUBLIC RELATIONS; REVIEW; UNITED STATES; UTILIZATION REVIEW; VACCINATION;

BIOTERRORISM; COST OF ILLNESS; DISASTER PLANNING; GUIDELINES; HEALTH CARE COSTS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; INTERINSTITUTIONAL RELATIONS; MASS IMMUNIZATION; PUBLIC HEALTH ADMINISTRATION; UNITED STATES; VACCINATION;

EID: 33746851574     PISSN: 15387135     EISSN: None     Source Type: Journal    
DOI: 10.1089/bsp.2006.4.20     Document Type: Review

References (218)

1. U.S. Department of State. U.S. Health Secretary Calls Bird Flu Outbreak Urgent Challenge. Washington, DC: U.S. Department of State; 2005. Available at: http://us-info.state.gov/gi/Archive/2005/May/16-413291.html. Accessed August 24, 2005.
2. Poland G. If you could halve the mortality rate, would you do it? Clin Infect Dis Aug 15 2002;35(4):378-380.
3. Glezen P. Influenza vaccination for healthy children. Curr Opin Infect Dis 2002;15:283-287.
4. Committee on Infectious Diseases. American Academy of Pediatrics. Reduction of the influenza burden in children. Pediatrics 2002;110(6):1246-1252.
5. Snacken R. Control of influenza. Public health policies. Vaccine Oct 29 1999;17(Suppl 3):S61-S63.
6. Glezen WP. Influenza control-unfinished business. JAMA Mar 10 1999;281(10):944-945.
7. World Health Organization. Influenza. Report by the Secretariat. Geneva: World Health Organization; November 26, 2002. Available at: http://www.who.int/ gb/ebwha/pdf_files/EB111/eeb11110.pdf. Accessed January 18, 2006.
8. Cox NJ, Tamblyn SE, Tam T. Influenza pandemic planning. Vaccine May 1 2003;21(16):1801-1803.
9. Patriarca PA, Cox NJ. Influenza pandemic preparedness plan for the United States. J Infect Dis Aug 1997;176(Suppl 1):S4-S7.
10. Strikas RA, Wallace GS, Myers MG. Influenza pandemic preparedness action plan for the United States: 2002 update. Clin Infect Dis Sep 1 2002;35(5):590-596.
11. U.S. Department of Health & Human Services. Healthy People 2010: Volume I, Objectives for Improving Health (Part A: Focus Areas 14). 2nd ed. Washington, DC: U.S. Department of Health & Human Services; January 30, 2001.
12. Centers for Disease Control and Prevention. Pandemic Influenza: A Planning Guide for State and Local Officials, version 2.1 - State and Local Pandemic Planning Guide. Atlanta: Centers for Disease Control and Prevention; February 17, 2004.
13. Madjid M, Naghavi M, Litovsky S, Casscells SW. Influenza and cardiovascular disease: a new opportunity for prevention and the need for further studies. Circulation Dec 2 2003;108(22):2730-2736.
14. Neuzil KM. Influenza vaccine for children. Clin Infect Dis Mar 1 2004;38(5):689-691.
15. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep Jul 29 2005;54(RR-8):1-40.
16. Madjid M, Lillibridge S, Mirhaji P, Casscells W. Influenza as a bioweapon. J R Soc Med 2003;96(7):345-346.
17. Fedson DS. Pandemic influenza and the global vaccine supply. Clin Infect Dis Jun 15 2003;36(12):1552-1561.
18. De Jong JC, Rimmelzwaan GF, Fouchier RA, Osterhaus AD. Influenza virus: a master of metamorphosis. J Infect 2000;40(3):218-228.
19. Influenza. In: Epidemiology and Prevention of Vaccine-Preventable Diseases - The Pink Book. Atlanta: National Immunization Program; chap. 15. Available at: http://www.cdc.gov/nip/publications/pink/flu.pdf. Accessed February 17, 2003.
20. Cox NJ, Fukuda K. Influenza. Infect Dis Clin North Am 1998;12(1):27-38.
21. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine Jul 30 1999;17(Suppl 1):S3-S10.
22. Miller MA. Considerations for adding pneumonia and influenza vaccines to public health programmes. Vaccine Jul 30 1999;17(Suppl 1):S95-S98.
23. Monto AS. Influenza: quantifying morbidity and mortality. Am J Med Jun 19 1987;82(6A):20-25.
24. Klimov A, Simonsen L, Fukuda K, Cox N. Surveillance and impact of influenza in the United States. Vaccine Jul 30 1999;17(Suppl 1):S42-S46.
25. Centers for Disease Control and Prevention. Influenza (flu) - Questions & Answers: The Disease. Atlanta: Centers for Disease Control and Prevention; 2005. Available at: http://www.cdc.gov/flu/about/qa/disease.htm. Accessed January 18, 2006.
26. Neuzil KM, Mellen BG, Wright PF, Mitchel EF Jr, Griffin MR. The effect of influenza on hospitalizations, outpatient visits, and courses of antibiotics in children. N Engl J Med Jan 27 2000;342(4):225-231.
27. Terebuh P, Uyeki T, Fukuda K. Impact of influenza on young children and the shaping of United States influenza vaccine policy. Pediatr Infect Dis J 2003;22(10):S231-S235.
28. Neuzil KM, Zhu Y, Griffin MR, et al. Burden of interpandemic influenza in children younger than 5 years: a 25-year prospective study. J Infect Dis Jan 15 2002;185(2):147-152.
29. Poland GA, Tosh P, Jacobson RM. Requiring influenza vaccination for health care workers: seven truths we must accept. Vaccine Mar 18 2005;23(17-18):2251-2255.
30. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA Jan 8 2003;289(2):179-186.
31. Morens DM. Influenza-related mortality: considerations 1for practice and public health. JAMA Jan 8 2003;289(2):227-229.
32. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA Sep 15 2004;292(11):1333-1340.
33. O'Brien MA, Uyeki TM, Shay DK, et al. Incidence of outpatient visits and hospitalizations related to influenza in infants and young children. Pediatrics 2004;113(3 Pt 1):585-593.
34. Silka PA, Geiderman JM, Goldberg JB, Kim LP. Demand on ED resources during periods of widespread influenza activity. Am J Emerg Med 2003;21(7):534-539.
35. Glaser CA, Gilliam S, Thompson WW, et al. Medical care capacity for influenza outbreaks, Los Angeles. Emerg Infect Dis 2002;8(6):569-574.
36. Neuzil KM, Wright PF, Mitchel EF Jr, Griffin MR. The burden of influenza illness in children with asthma and other chronic medical conditions. J Pediatr 2000;137 (6):856-864.
37. Szucs T. The socio-economic burden of influenza. J Antimicrob Chemother Nov 1999;44(Suppl B):11-15.
38. Gerdil C. The annual production cycle for influenza vaccine. Vaccine May 1 2003;21(16):1776-1779.
39. National Foundation for Infectious Diseases. Increasing Influenza Immunization Rates in Infants and Children: Putting Recommendations into Practice. Bethesda, Md: National Foundation for Infectious Diseases; 2003. Available at: http://www.nfid.org/publications/pediatricflu.pdf. Accessed January 18, 2006.
40. Nichol KL. The efficacy, effectiveness and cost-effectiveness of inactivated influenza virus vaccines. Vaccine May 1 2003;21(16):1769-1775.
41. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons. A meta-analysis and review of the literature. Ann Intern Med Oct 1 1995;123(7):518-527.
42. Ruben FL. Inactivated influenza virus vaccines in children. Clin Infect Dis Mar 1 2004;38(5):678-688.
43. Negri E, Colombo C, Giordano L, Groth N, Apolone G, La Vecchia C. Influenza vaccine in healthy children: a meta-analysis. Vaccine Apr 22 2005;23(22):2851-2861.
44. Vu T, Farish S, Jenkins M, Kelly H. A meta-analysis of effectiveness of influenza vaccine in persons aged 65 years and over living in the community. Vaccine Mar 15 2002;20(13-14):1831-1836.
45. Jefferson T, Rivetti D, Rivetti A, Rudin M, Di Pietrantonj C, Demicheli V. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review. Lancet Oct 1 2005;366(9492):1165-1174.
46. Naghavi M, Barlas Z, Siadaty S, Naguib S, Madjid M, Casscells W. Association of influenza vaccination and reduced risk of recurrent myocardial infarction. Circulation Dec 19 2000;102(25):3039-3045.
47. Siscovick DS, Raghunathan TE, Lin D, et al. Influenza vaccination and the risk of primary cardiac arrest. Am J Epidemiol Oct 1 2000;152(7):674-677.
48. Gurfinkel EP, de la Fuente RL, Mendiz O, Mautner B. Influenza vaccine pilot study in acute coronary syndromes and planned percutaneous coronary interventions: the FLU Vaccination Acute Coronary Syndromes (FLUVACS) Study. Circulation May 7 2002;105(18):2143-2147.
49. Lavallee P, Perchaud V, Gautier-Bertrand M, Grabli D, Amarenco P. Association between influenza vaccination and reduced risk of brain infarction. Stroke 2002;33(2):513-518.
50. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995;149(10):1113-1117.
51. Glezen WP. Prevention of acute otitis media by prophylaxis and treatment of influenza virus infections. Vaccine Dec 8 2000;19(Suppl 1):S56-S58.
52. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991;145(4):445-448.
53. Kramarz P, Destefano F, Gargiullo PM, et al. Does influenza vaccination prevent asthma exacerbations in children? J Pediatr 2001;138(3):306-310.
54. Hak E, Buskens E, van Essen GA, et al. Clinical effectiveness of influenza vaccination in persons younger than 65 years with high-risk medical conditions: the PRISMA study. Arch Intern Med Feb 14 2005;165(3):274-280.
55. Glezen WP, Simonsen L. Commentary: Benefits of influenza vaccine in US elderly-new studies raise questions. Int J Epidemiol Dec 20 2005. [Epub ahead of print]
56. Kelly H, Vu T, Smith D. Influenza vaccination and mortality in the United States. Arch Intern Med Sep 26 2005;165(17):2037-2038;author reply 2039-2040.
57. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox NJ, Fukuda K. Influenza vaccination among the elderly in the United States. Arch Intern Med Sep 26 2005;165(17):2038-2039; author reply 2039-2040.
58. Nichol KL, Fedson DS. Should we question the benefits of influenza vaccination for the elderly? Infectious Disease News August 2005. Available at: http://www.infectiousdiseasenews.com/200508/frameset.asp?article=guested1.asp. Accessed December 27, 2005.
59. Simonsen L, Viboud C, Blackwelder WC, Taylor R, Miller M. Researchers defend influenza vaccine study. Infectious Disease News August 2005. Available at: http://www.infectiousdiseasenews.com/200508/frameset.asp?article=guested2. asp. Accessed December 27, 2005.
60. Reichert TA, Christensen RA. Enhance the national influenza vaccination strategy. Infectious Disease News August 2005. Available at: http://www.infectiousdiseasenews.com/200508/frameset.asp?article= guested3.asp. Accessed December 27, 2005.
61. Simonsen L, Reichert TA, Viboud C, Blackwelder WC, Taylor RJ, Miller MA. Impact of influenza vaccination on seasonal mortality in the US elderly population. Arch Intern Med Feb 14 2005;165(3):265-272.
62. Jackson LA, Jackson ML, Nelson JC, Neuzil KM, Weiss NS. Evidence of bias in estimates of influenza vaccine effectiveness in seniors. Int J Epidemiol Dec 20 2005. [Epub ahead of print]
63. Jackson LA, Nelson JC, Benson P, et al. Functional status is a confounder of the association of influenza vaccine and risk of all cause mortality in seniors. Int J Epidemiol Dec 20 2005. [Epub ahead of print]
64. Hurwitz ES, Haber M, Chang A, et al. Effectiveness of influenza vaccination of day care children in reducing influenza-related morbidity among household contacts. JAMA Oct 4 2000;284(13):1677-1682.
65. Herzog NS, Bratzler DW, Houck PM, et al. Effects of previous influenza vaccination on subsequent readmission and mortality in elderly patients hospitalized with pneumonia. Am J Med Oct 15 2003;115(6):454-461.
66. Wang CS, Wang ST, Lai CT, Lin LJ, Lee CT, Chou P. Reducing major cause-specific hospitalization rates and shortening hospital stays after influenza vaccination. Clin Infect Dis Dec 1 2004;39(11):1604-1610.
67. Wilde JA, McMillan JA, Serwint J, Butta J, O'Riordan MA, Steinhoff MC. Effectiveness of influenza vaccine in health care professionals: a randomized trial. JAMA Mar 10 1999;281(10):908-913.
68. Nichol KL, Nordin J, Mullooly J, Lask R, Filibrandt K, Iwane M. Influenza vaccination and reduction in hospitalizations for cardiac disease and stroke among the elderly. N Engl J Med Apr 3 2003;348(14):1322-1332.
69. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med Sep 22 1994;331(12):778-784.
70. Nichol KL, Goodman M. Cost effectiveness of influenza vaccination for healthy persons between ages 65 and 74 years. Vaccine May 15 2002;20(Suppl 2):S21-S24.
71. Riddiough MA, Sisk JE, Bell JC. Influenza vaccination. JAMA Jun 17 1983;249(23):3189-3195.
72. Office of Technology Assessment. Cost Effectiveness of Influenza Vaccination. Washington, DC: Office of Technology Assessment; 1981. Available at: http://www.wws. princeton.edu/cgi-bin/byteserv.prl/~ota/disk3/1981/8112/ 8112.PDF. Accessed February 17, 2003.
73. Nichol KL. Cost-benefit analysis of a strategy to vaccinate healthy working adults against influenza. Arch Intern Med Mar 12 2001;161(5):749-759.
74. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med Oct 5 1995;333(14):889-893.
75. Nichol KL, Mallon KP, Mendelman PM. Cost benefit of influenza vaccination in healthy, working adults: an economic analysis based on the results of a clinical trial of trivalent live attenuated influenza virus vaccine. Vaccine May 16 2003;21(17-18):2207-2217.
76. Bridges CB, Thompson WW, Meltzer MI, et al. Effectiveness and cost-benefit of influenza vaccination of healthy working adults: A randomized controlled trial. JAMA Oct 4 2000;284(13):1655-1663.
77. Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med Mar 2 1999;130(5):397-403.
78. Nichol KL, Wuorenma J, von Sternberg T. Benefits of influenza vaccination for low-, intermediate-, and high-risk senior citizens. Arch Intern Med Sep 14 1998;158(16):1769-1776.
79. Perez-Tirse J, Gross PA. Review of cost-benefit analyses of influenza vaccine. Pharmacoeconomics 1992;2(3):198-206.
80. Postma MJ, Baltussen RM, Heijnen ML, de Berg LT, Jager JC. Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence. Drugs Aging 2000;17(3):217-227.
81. Nichol KL. Clinical effectiveness and cost effectiveness of influenza vaccination among healthy working adults. Vaccine Jul 30 1999;17(Suppl 1):S67-S73.
82. Wood SC, Nguyen VH, Schmidt C. Economic evaluations of influenza vaccination in healthy working-age adults. Employer and society perspective. Pharmacoeconomics 2000;18(2):173-183.
83. White T, Lavoie S, Nettleman MD. Potential cost savings attributable to influenza vaccination of school-aged children. Pediatrics 1999;103(6):e73.
84. Postma MJ, Jansema P, van Genugten ML, Heijnen ML, Jager JC, de Jong-van den Berg LT. Pharmacoeconomics of influenza vaccination for healthy working adults: reviewing the available evidence. Drugs 2002;62(7):1013-1024.
85. Rothberg MB, Rose DN. Vaccination versus treatment of influenza in working adults: a cost-effectiveness analysis. Am J Med 2005;118(1):68-77.
86. Meltzer MI, Neuzil KM, Griffin MR, Fukuda K. An economic analysis of annual influenza vaccination of children. Vaccine Jan 11 2005;23(8):1004-1014.
87. Luce BR, Zangwill KM, Palmer CS, et al. Cost-effectiveness analysis of an intranasal influenza vaccine for the prevention of influenza in healthy children. Pediatrics Aug 2001;108(2):E24.
88. Cohen GM, Nettleman MD. Economic impact of influenza vaccination in preschool children. Pediatrics 2000;106(5):973-976.
89. Centers for Disease Control and Prevention. Advisory Committee on Immunization Practices. Atlanta: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services; November 2005. Available at: http://www.cdc.gov/nip/ACIP/default.htm. Accessed January 18, 2006.
90. st Century. Washington, DC: Institute of Medicine; 2004.
91. Abramson JS, Neuzil KM, Tamblyn SE. Annual universal influenza vaccination: ready or not? Clin Infect Dis Jan 1 2006;42(1):132-135.
92. Enserink M. Influenza. Crisis underscores fragility of vaccine production system. Science Oct 15 2004;306 (5695):385.
93. O'Mara D, Fukuda K, Singleton JA. Influenza vaccine: ensuring timely and adequate supplies. Infect Med 2003;20(11):548-554.
94. Fukuda K, O'Mara D, Singleton JA. How the delayed distribution of influenza vaccine created shortages in 2000 and 2001. Pharmacol Ther 2002;27(5):235-242.
95. Cox NJ. The Current Season: A Review of the 2003-04 influenza Season. Atlanta: Centers for Disease Control and Prevention; February 2004. Available at: www.hhs.gov/nvpo/meetings/feb2004/cox.ppt. Accessed November 30, 2004.
96. Updated interim influenza vaccination recommendations-2004-05 influenza season. MMWR Morb Mortal Wkly Rep Dec 24 2004;53(50):1183-1184.
97. Centers for Disease Control and Prevention. Revised Interim Guidance for Late-Season Influenza Vaccination. Atlanta: Centers for Disease Control and Prevention; January 27, 2005. Available at: http://www.cdc.gov/flu/protect/ lateseasonguidance.htm. Accessed January 18, 2006.
98. Schoch-Spana M, Fitzgerald J, Kramer BR. Influenza vaccine scarcity 2004-05: implications for biosecurity and public health preparedness. Biosecur Bioterror 2005;3(3):224-234.
99. Rosenwald MS. Britain allows Chiron to resume making vaccine. Washington Post March 3, 2005:E01.
100. Stein R. Vaccine shortage turns to surplus; U.S. is likely to lift restrictions and urge flu shots. Washington Post January 22, 2005:A01.
101. Schneider EC, Cleary PD, Zaslavsky AM, Epstein AM. Racial disparity in influenza vaccination: does managed care narrow the gap between African Americans and whites? JAMA Sep 26 2001;286(12):1455-1460.
102. Armstrong K, Berlin M, Schwartz JS, Propert K, Ubel PA. Barriers to influenza immunization in a low-income urban population. Am J Prev Med 2001;20(1):21-25.
103. Racial/ethnic disparities in influenza and pneumococcal vaccination levels among persons aged > or =65 years-United States, 1989-2001. MMWR Morb Mortal Wkly Rep Oct 10 2003;52(40):958-962.
104. Marin MG, Johanson WG Jr, Salas-Lopez D. Influenza vaccination among minority populations in the United States. Prev Med 2002;34(2):235-241.
105. Reasons reported by Medicare beneficiaries for not receiving influenza and pneumococcal vaccinations-United States, 1996. MMWR Morb Mortal Wkly Rep Oct 8 1999;48(39):886-890.
106. Zimmerman RK, Santibanez TA, Janosky JE, et al. What affects influenza vaccination rates among older patients? An analysis from inner-city, suburban, rural, and veterans affairs practices. Am J Med 2003;114(1):31-38.
107. Steiner M, Vermeulen LC, Mullahy J, Hayney MS. Factors influencing decisions regarding influenza vaccination and treatment: a survey of healthcare workers. Infect Control Hosp Epidemiol 2002;23(10):625-627.
108. Influenza vaccination and self-reported reasons for not receiving influenza vaccination among Medicare beneficiaries aged > or =65 years-United States, 1991-2002. MMWR Morb Mortal Wkly Rep Dec 5 2004;53(43):1012-1015.
109. Experiences with obtaining influenza vaccination among persons in priority groups during a vaccine shortage-United States, October-November, 2004. MMWR Morb Mortal Wkly Rep Dec 17 2004;53(49):1153-1155.
110. Jones TF, Ingram LA, Craig AS, Schaffner W. Determinants of influenza vaccination, 2003-2004: shortages, fallacies and disparities. Clin Infect Dis Dec 15 2004;39(12):1824-1828.
111. Desroches CM, Blendon RJ, Benson JM. Americans' responses to the 2004 influenza vaccine shortage. Health Aff (Millwood) 2005;24(3):822-831.
112. Helms CM, Guerra FA, Klein JO, Schaffner W, Arvin AM, Peter G. Strengthening the nation's influenza vaccination system: a National Vaccine Advisory Committee assessment. Am J Prev Med 2005;29(3):221-226.
113. Santoli JM, Peter G, Arvin AM, et al. Strengthening the supply of routinely recommended vaccines in the United States: recommendations from the National Vaccine Advisory Committee. JAMA Dec 17 2003;290(23):3122-3128.
114. Poland GA, Marcuse EK. Vaccine availability in the US: problems and solutions. Nat Immunol 2004;5(12):1195-1198.
115. Fedson DS. Preparing for pandemic vaccination: an international policy agenda for vaccine development. J Public Health Policy 2005;26(1):4-29.
116. U.S. General Accounting Office. Influenza Pandemic - Plan Needed for Federal and State Response. Washington, DC: U.S. General Accounting Office; October 2000. GAO-01-4.
117. Danzon PM, Pereira NS, Tejwani SS. Vaccine supply: a cross-national perspective. Health Aff (Millwood) 2005;24(3):706-717.
118. Committee on Government Reform. A Review of This Year's Flu Season: Does Our Public Health System Need a Shot in the Arm? 108th Congress ed. Washington DC: Committee on Government Reform; 2004.
119. Centers for Disease Control and Prevention. Influenza Vaccine Bulletin #2-Flu Season 2005-06. Atlanta: Centers for Disease Control and Prevention; 2005. Available at: http://www.cdc.gov/flu/professionals/bulletin/2005-06/ bulletin2_090805.htm. Accessed September 13, 2005.
120. Centers for Disease Control and Prevention. Influenza Vaccine Bulletin #3-Flu Season 2005-06. Atlanta: Centers for Disease Control and Prevention; 2005. Available at: http://www.cdc.gov/flu/professionals/bulletin/2005-06/ bulletin3_092905.htm. Accessed October 4, 2005.
121. Manning A. New, deadly flu pandemic 'inevitable,' experts warn. USA Today March 2, 2004:8D.
122. Osterholm MT. Preparing for the next pandemic. N Engl J Med May 5 2005;352(18):1839-1842.
123. Nuzzo J. The next pandemic? Biosecurity Bulletin Autumn 2004;6(2):1-3. Available at: http://www.upmc-biosecurity.org/pages/publications/pdf/ bulletin_6_2.pdf. Accessed January 18, 2006.
124. Guan Y, Poon LL, Cheung CY, et al. H5N1 influenza: a protean pandemic threat. Proc Natl Acad Sci U S A May 25 2004;101(21):8156-8161.
125. Meltzer MI, Cox NJ, Fukuda K. The economic impact of pandemic influenza in the United States: priorities for intervention. Emerg Infect Dis 1999;5(5):659-671.
126. Trust for America's Health. A Killer Flu? Washington, DC: Trust for America's Health; 2005. Available at: http://healthyamericans.org/reports/flu/ Flu2005.pdf. Accessed June 29, 2005.
127. Enserink M. Avian influenza. 'Pandemic vaccine' appears to protect only at high doses. Science Aug 12 2005;309(5737):996.
128. U.S. Department of Health and Human Services. HHS Pandemic Influenza Plan. Washington, DC: U.S. Department of Health and Human Services; November 2005. Available at: http://www.hhs.gov/pandemicflu/plan/pdf/ HHSPandemicInfluenzaPlan.pdf. Accessed December 5, 2005.
129. Center for Biosecurity of UPMC. National Strategy for Pandemic Influenza and the HHS Pandemic Influenza Plan: Thoughts and Comments from the Center for Biosecurity of UPMC. Baltimore, Md: Center for Biosecurity of UPMC; November 7, 2005. Available at: http://www. upmc-biosecurity.org/avianflu/comments-fluplan. html. Accessed December 5, 2005.
130. Levi J, Inglesby T. Working Group on Pandemic Influenza Preparedness: joint statement in response to Department of Health and Human Services Pandemic Influenza Plan. Clin Infect Dis Jan 1 2006;42(1):92-94.
131. Hearne SA, Segal LM, Earls MJ, Unruh PJ. Ready or Not? Protecting the Public's Health in the Age of Bioterrorism 2004. Washington, DC: Trust for America's Health; 2004. Available at: http://healthyamericans.org/reports/ bioterror04/BioTerror04Report.pdf. Accessed December 16, 2004.
132. Hearne SA, Segal LM, Earls MJ, Juliano C, Stephens T. Ready or Not? Protecting the Public's Health from Disease, Disasters, and Bioterrorism, 2005. Washington, DC: Trust for America's Health; December 2005. Available at: http://healthyamericans.org/reports/bioterror05/bioterror05Report.pdf. Accessed December 5, 2005.
133. Webby RJ, Webster RG. Are we ready for pandemic influenza? Science Dec 28 2003;302(5650):1519-1522.
134. Kaiser J. Influenza: girding for disaster. Facing down pandemic flu, the world's defenses are weak. Science Oct 15 2004;306(5695):394-397.
135. Heinrich J. Infectious Disease Preparedness-Federal Challenges in Responding to Influenza Outbreaks. Washington, DC: U.S. Government Accountability Office; 2004. Available at: http://www.gao.gov/new.items/ d041100t.pdf. Accessed December 16, 2004.
136. Earls MJ, Hearne SA. Facing the Flu: From the Bird Flu to a Possible Pandemic, Why Isn't America Ready? Washington, DC: Trust for America's Health; 2005. Available at: http://healthyamericans.org/reports/files/AvianFlu.pdf. Accessed February 9, 2005.
137. Mintz J, Warrick J. U.S. unprepared despite progress, experts say. Washington Post November 8, 2004:A01.
138. Hall M. Cities fret over how to quickly deliver vaccines. USA Today August 1, 2005:3A.
139. Hall M. Nation unready for germ attacks; bioterror defense lags despite 4 years, $20B. USA Today August 1, 2005:1A.
140. Centers for Disease Control and Prevention. CDC Guidance for Post-Event Smallpox Planning. Atlanta: Centers for Disease Control and Prevention; 2003. Available at: http://www.bt.cdc.gov/agent/smallpox/prep/post-event-guidance.asp. Accessed February 18, 2003.
141. Democratic Members of the House Select Committee on Homeland Security. A Biodefense Failure: The National Smallpox Vaccination Program One Year Later. January 2004. Available at: http://hsc-democrats.house.gov/NR/rdonlyres/ 0F6A8458-6EE8-455D-8E0E-C7C7239-D403A/0/biodefensefailure.pdf. Accessed January 18, 2006.
142. Bioterrorism: America Still Unprepared. Democratic Staff of the House Select Committee on Homeland Security. Available at: http://www.house.gov/hsc/ democrats/pdf/hsc_docs/finalreportwithcover.pdf. Accessed October 25, 2004.
143. Rauch J. Smallpox is Bush's worst failure. But he can fix the problem. National Journal November 14 2003. Available at: http://nationaljournal.corn/ members/buzz/2003/socialstudies/111403.htm. Accessed January 18, 2006.
144. McGlinchey D. The smallpox shuffle. Government Executive April 7, 2004. Available at: http://www.govexec. com/features/0404-1/0404-Inewsanalysis2.htm. Accessed January 18, 2006.
145. Manning A. Universal flu shots considered. USA Today February 25, 2004:9D.
146. Munoz FM. Influenza virus infection in infancy and early childhood. Paediatr Respir Rev 2003;4(2):99-104.
147. Longini IM Jr, Koopman JS, Monto AS, Fox JP. Estimating household and community transmission parameters for influenza. Am J Epidemiol 1982;115(5):736-751.
148. Poland GA, Hall CB. Influenza immunization of schoolchildren: can we interrupt community epidemics? Pediatrics 1999;103(6 Pt 1):1280-1282.
149. Jordan R, Connock M, Albon E, et al. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine Sep 26 2005. [Epub ahead of print]
150. Monto AS, Davenport FM, Napier JA, Francis T Jr. Effect of vaccination of a school-age population upon the course of an A2-Hong Kong influenza epidemic. Bull World Health Organ 1969;41(3):537-542.
151. Longini IM, Halloran ME, Nizam A, et al. Estimation of the efficacy of live, attenuated influenza vaccine from a two-year, multi-center vaccine trial: implications for influenza epidemic control. Vaccine Mar 17 2000;18(18):1902- 1909.
152. Piedra PA, Gaglani MJ, Kozinetz CA, et al. Herd immunity in adults against influenza-related illnesses with use of the trivalent-live attenuated influenza vaccine (CAIV-T) in children. Vaccine Feb 18 2005;23(13):1540-1548.
153. Halloran ME, Longini IM, Cowart DM, Nizam A. Community interventions and the epidemic prevention potential. Vaccine Sep 10 2002;20(27-28):3254-3262.
154. Weycker D, Edelsberg J, Halloran ME, et al. Population-wide benefits of routine vaccination of children against influenza. Vaccine Jan 26 2005;23(10):1284-1293.
155. Longini IM Jr, Halloran ME. Strategy for distribution of influenza vaccine to high-risk groups and children. Am J Epidemiol 2005;161(4):303-306.
156. Reichert TA, Sugaya N, Fedson DS, Glezen WP, Simonsen L, Tashiro M. The Japanese experience with vaccinating schoolchildren against influenza. N Engl J Med Mar 22 2001;344(12):889-896.
157. McBean AM, Hebert PL. New estimates of influenza-related pneumonia and influenza hospitalizations among the elderly. Int J Infect Dis 2004;8(4):227-235.
158. Fedson DS. Vaccination for pandemic influenza: a six point agenda for interpandemic years. Pediatr Infect Dis J 2004;23(1 Suppl):S74-S77.
159. Orenstein WA. Purchase Options For Influenza Vaccines in the Setting of a Pandemic. Atlanta: Emory University; 2005. Available at: http://www.hhs.gov/ nvpo/nvac/documents/Pandemicinfluvac.PPT. Accessed August 23, 2005.
160. Bardiya N, Bae JH. Influenza vaccines: recent advances in production technologies. Appl Microbiol Biotechnol May 2005;67(3):299-305.
161. Citizen Voices on Pandemic Flu Choices - A Report of the Public Engagement Pilot on Pandemic Influenza. Atlanta: Public Engagement Pilot Project on Pandemic Influenza; December 2005. Available at: http://www.keystone.org/ FINALREPORT_PEPPPI_DEC_2005.pdf. Accessed January 11, 2006.
162. Working Group on "Governance Dilemmas" in Bioterrorism Response. Leading during bioattacks and epidemics with the public's trust and help. Biosecur Bioterror 2004;2(1):25-40.
163. Lindell MK, Perry RW. Behavioral Foundations of Community Emergency Planning. Washington, DC: Hemisphere Publishing; 1992.
164. Mair M, Mair JS. A complementary approach to bioterrorism prevention. Nonproliferation Review Fall-Winter 2003;10(3):114-124.
165. Committee on Smallpox Vaccination Program Implementation. Baciu A, Anason AP, Stratton K, Strom B, eds. The Smallpox Vaccination Program - Public Health in the Age of Terrorism. Washington DC: National Academies Press; 2005.
166. Centers for Disease Control and Prevention. CDC Vaccine Price List. Atlanta: National Immunization Program, Centers for Disease Control and Prevention; August 1, 2005. Available at: http://www.cdc.gov/nip/vfc/ cdc_vac_price_list.htm. Accessed August 1, 2005.
167. McGuire TG. Setting prices for new vaccines (in advance). Int J Health Care Finance Econ 2003;3(3):207-224.
168. Rappuoli R, Miller HI, Falkow S. Medicine. The intangible value of vaccination. Science Aug 9 2002;297(5583):937-939.
169. Kaufmann AF, Meltzer MI, Schmid GP. The economic impact of a bioterrorist attack: are prevention and postattack intervention programs justifiable? Emerg Infect Dis 1997;3(2):83-94.
170. Economic Risks Associated with an Influenza Pandemic. Testimony of James Newcomb, Managing Director for Research, Bio Economic Research Associates, before the Senate Committee on Foreign Relations November 9, 2005. Available at: http://foreign.senate.gov/testimony/2005/NewcombTestimony051109.pdf. Accessed December 9, 2005.
171. U.S. Government Accountability Office. Emerging Infectious Diseases: Asian SARS Outbreak Challenged International and National Responses. Washington, DC: U.S. Government Accountability Office; April 2004. GAO-04-564.
172. Heyman D. Lessons from the Anthrax Attacks: Implications for U.S. Bioterrorism Preparedness. Washington, DC: Center for Strategic and International Studies and the Defense Threat Reduction Agency; 2002. Available at: http://www.fas.org/irp/threat/cbw/dtra02.pdf. Accessed August 15, 2005.
173. Orenstein WA, Douglas RG, Rodewald LE, Hinman AR. Immunizations in the United States: success, structure, and stress. Health Aff (Millwood) 2005;24(3):599-610.
174. Hinman AR, Orenstein WA, Rodewald L. Financing immunizations in the United States. Clin Infect Dis May 15 2004;38(10):1440-1446.
175. Mair JS, Mair M. Vaccine liability in the era of bioterrorism. Biosecur Bioterror 2003;1(3):169-184.
176. Duke EM. National Vaccine Injury Compensation Program: Addition of trivalent influenza vaccines in the injury table. Federal Register April 12 2005;70(69):19092-19093.
177. U.S. Department of Health and Human Services. National Vaccine Injury Compensation Program Fact Sheet. Washington, DC: U.S. Department of Health and Human Services. Available at: http://www.hrsa.gov/osp/vicp/fact_sheet.htm. Accessed October 11, 2005.
178. U.S. Department of Health and Human Services. Commonly Asked Questions About the National Vaccine Injury Compensation Program. Washington, DC: U.S. Department of Health and Human Services; December 18, 2002. Available at: http://www.hrsa.gov/osp/vicp/QANDA. HTM. Accessed January 18, 2006.
179. Stratton K, Alamario DA, Wizemann T, McCormick MC. Immunization Safety Review - Influenza Vaccines and Neurological Complications. Washington, DC: National Academies Press; 2004.
180. Izurieta HS, Haber P, Wise RP, et al. Adverse events reported following live, cold-adapted, intranasal influenza vaccine. JAMA Dec 7 2005;294(21):2720-2725.
181. Mello MM, Brennan TA. Legal concerns and the influenza vaccine shortage. JAMA October 12 2005;294(14):1817-1820.
182. U.S. Department of Health and Human Services. National Childhood Vaccine Injury Act Vaccine Injury Table. Washington, DC: U.S. Department of Health and Human Services; July 1, 2005. Available at: http://www.hrsa.gov/osp/vicp/table. htm. Accessed January 18, 2006.
183. A Bill to amend the Public Health Service Act with respect to the National Vaccine Injury Compensation Program, H.R. 1297, 109th Cong., 1st. Sess.(2005).
184. Daems R, Del Giudice G, Rappuoli R. Anticipating crisis: towards a pandemic flu vaccination strategy through alignment of public health and industrial policy. Vaccine Dec 30 2005;23(50):5732-5742.
185. Public Readiness and Emergency Preparedness Act, 109 Pub. L. 148; 119 Stat. 2680 (2005) (codified at 42 U.S.C.S. §§247d-6d; 247d-6e).
186. Alonso-Zaldivar R. Bird-flu bill slammed as loop-hole for drugmakers. Los Angeles Times December 19, 2005. Available at: http://www.latimes.com/news/ nationworld/nation/1a-121905vaccine_lat,0,643132, print.story?coll=1a-home- headlines. Accessed December 27, 2005.
187. Democratic Policy Committee. Republican Leadership is Delaying Defense Funding for Controversial Riders. Washington, DC: Democratic Policy Committee; December 20, 2005. Available at: http://democrats.senate.gov/dpc/dpc-new.cfm? doc_name=fs-109-1-144. Accessed December 27, 2005.
188. Centers for Disease Control and Prevention. Influenza Vaccine Bulletin #1-Flu Season 2005-06. Atlanta: Centers for Disease Control and Prevention; 2005. Available at: http://www.cdc.gov/flu/professionals/bulletin/2005-06/ bulletin1_062905.htm. Accessed July 1, 2005.
189. National Center for Health Statistics. Early Release of Selected Estimates Based on Data From the 2004 National Health Interview Survey-influenza Shot. Hyattsville, Md: National Center for Health Statistics, Centers for Disease Control and Prevention; 2005. Available at: http://www.cdc.gov/nchs/ data/nhis/earlyrelease/200506_04.pdf. Accessed September 13, 2005.
190. Estimated influenza vaccination coverage among adults and children - United States, September 1-November 30, 2004. MMWR Morb Mortal Wkly Rep Dec 17 2004;53(49):1147-1153.
191. Estimated influenza vaccination coverage among adults and children - United States, September 1, 2004-January 31, 2005. MMWR Morb Mortal Wkly Rep Apr 1 2005;54(12):304-307.
192. Centers for Disease Control and Prevention. Overview of influenza Surveillance in the United States. Atlanta: Centers for Disease Control and Prevention; 2004. Available at: http://www.cdc.gov/flu/weekly/pdf/flu- surveillance-overview.pdf. Accessed November 23, 2004.
193. Harper SA, Fukuda K, Uyeki TM, Cox NJ, Bridges CB. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep May 28 2004;53(RR-6):1-40.
194. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997;87(12):1944-1950.
195. Anderson RN. National Vital Statistics Report-Deaths: Leading Causes for 2000. Hyattsville, Md: National Center for Health Statistics, Centers for Disease Control and Prevention; September 16, 2002. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr50/nvsr50_16.pdf. Accessed October 18, 2003.
196. Arias E, Anderson RN, Kung H, Murphy S, Kochanek KD. National Vital Statistics Report-Deaths: Final Data for 2001. Atlanta: Centers for Disease Control and Prevention; September 18, 2003. Available at: http://www. cdc.gov/nchs/data/nvsr/nvsr52/nvsr52_03.pdf. Accessed October 18, 2003.
197. Anderson RN. National Vital Statistics Report-Deaths: Leading Causes for 1999. Atlanta: Centers for Disease Control and Prevention; October 12, 2001. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr49/nvsr49_11.pdf. Accessed October 18, 2003.
198. Kochanek KD, Betty L, Smith BS. National Vital Statistics Report-Deaths: Preliminary Data for 2002. Atlanta: Centers for Disease Control and Prevention; February 11, 2004. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr52/ nvsr52_13.pdf. January 18, 2006.
199. Hoyert DL, Kung H, Smith BL. National Vital Statistics Report-Deaths: Preliminary Data for 2003. Hyattsville, Md: National Center for Health Statistics, Centers for Disease Control and Prevention; February 28, 2005. Available at: http://www.cdc.gov/nchs/data/nvsr/nvsr53/nvsr53_15.pdf. Accessed January 9, 2005.
200. Gay NJ, Andrews NJ, Trotter CL, Edmunds WJ. Estimating deaths due to influenza and respiratory syncytial virus. JAMA May 21 2003;289(19):2499; author reply 2500-2492.
201. Simonsen L, Blackwelder WC, Reichert TA, Miller MA. Estimating deaths due to influenza and respiratory syncytial virus. JAMA May 21 2003;289(19):2499- 2500; author reply 2500-2492.
202. Glezen WP, Couch RB. Estimating deaths due to influenza and respiratory syncytial virus. JAMA May 21 2003;289(19):2500; author reply 2500-2502.
203. Dushoff J, Plotkin JB, Viboud C, Earn DJ, Simonsen L. Mortality due to influenza in the United States - an annualized regression approach using multiple-cause mortality data. Am J Epidemiol 2006;163(2):181-187.
204. Glezen WP. Emerging infections: pandemic influenza. Epidemiol Rev 1996;18(1):64-76.
205. Simonsen L, Fukuda K, Schonberger LB, Cox NJ. The impact of influenza epidemics on hospitalizations. J Infect Dis 2000;181(3):831-837.
206. National Center for Health Statistics. Vital Health & Health Statistics - Current Estimates from the National Health Interview Survey, 1996. Hyattsville, Md: National Center for Health Statistics, Centers for Disease Control and Prevention; October 1999. Available at: http://www.cdc.gov/nchs/ data/series/sr_10/sr10_200.pdf. Accessed January 18, 2006.
207. Meltzer MI. Introduction to health economics for physicians. Lancet Sep 22 2001;358(9286):993-998.
208. Palese P. Making better influenza virus vaccines? Emerg Infect Dis 2006;12(1):61-65.
209. Hehme N, Engelmann H, Kuenzel W, Neumeier E, Saenger R. Immunogenicity of a monovalent, aluminum-adjuvanted influenza whole virus vaccine for pandemic use. Virus Res Jul 2004;103(1-2):163-171.
210. Sanofi Pasteur announces preliminary trial results for a first H5N1 pre-pandemic influenza vaccine candidate with an adjuvant [press release]. Sanofi Pasteur; December 15, 2005. Available at: http://en.sanofi-aventis.com/ press/p_press.asp. Accessed December 19, 2005.
211. Rosenbaum S. The public-private dynamics of national immunization policy. Am J Prev Med 2000;19(3 Suppl):19-20.
212. National Immunization Program. Which Children are Eligible for the VFC Program? Atlanta: National Immunization Program, Centers for Disease Control and Prevention; January 27, 2004. Available at: http://www.cdc.gov/nip/vfc/Parent/ eligible_children.htm. Accessed August 5, 2005.
213. Centers for Disease Control and Prevention. Immunization Grant Program (Section 317). Atlanta: Centers for Disease Control and Prevention; January 2004. Available at: http://www.cdc.gov/programs/immun03.htm. Accessed August 19, 2005.
214. Centers for Disease Control and Prevention. Parents & VFC. Atlanta: Centers for Disease Control and Prevention; February 24, 2004. Available at: http://www.cdc. gov/nip/vfc/Parent/parent_home.htm. Accessed August 19, 2005.
215. Lien O, Franco C, Kwik Gronvall G, Maldin B, Borio B. Getting Medicine to Millions in a Public Health Emergency: Can Retailers Play a Role? Baltimore, Md: Center for Biosecurity, UPMC; 2005. Available at: http://www. upmc-biosecurity.org/misc/medicine/medicine.html. Accessed August 22, 2005.
216. Fairbrother G, Kuttner H, Miller W, et al. Findings from case studies of state and local immunization programs. Am J Prev Med 2000;19(3 Suppl):54-77.
217. Rodewald L. Federal Vaccine Purchase from the National Immunization Program's Perspective. Atlanta: Centers for Disease Control and Prevention; 2004. Available at: http://www.hhs.gov/nvpo/meetings/jun2004/Rodewald% 20-%20NVPO%20vaccine%20financing%20meeting.ppt. Accessed August 23, 2005.
218. Pauly MV. Improving vaccine supply and development: who needs what? Health Aff (Millwood) May-Jun 2005;24(3):680-689.